These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 6306429)

  • 1. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
    Enjalbert A; Bockaert J
    Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
    Munemura M; Agui T; Sibley DR
    Endocrinology; 1989 Jan; 124(1):346-55. PubMed ID: 2521206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture.
    Weiss S; Sebben M; Garcia-Sainz JA; Bockaert J
    Mol Pharmacol; 1985 Jun; 27(6):595-9. PubMed ID: 2987658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M-1 and M-2 muscarinic receptor-mediated inhibition of dopamine-sensitive adenylate cyclase in rat neostriatum: a permissive role for D-2 dopamine receptors.
    Schoffelmeer AN; Hogenboom F; Mulder AH
    J Pharmacol Exp Ther; 1988 May; 245(2):658-63. PubMed ID: 2452877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
    Lin C; McGonigle P; Molinoff PB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):950-6. PubMed ID: 2958621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
    Roseboom PH; Gnegy ME
    Mol Pharmacol; 1989 Jan; 35(1):139-47. PubMed ID: 2563306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
    Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
    J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of the angiotensin receptor negatively coupled with adenylate cyclase in rat anterior pituitary gland.
    Marie J; Gaillard RC; Schoenenberg P; Jard S; Bockaert J
    Endocrinology; 1985 Mar; 116(3):1044-50. PubMed ID: 2982569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells.
    Barton AC; Black LE; Sibley DR
    Mol Pharmacol; 1991 May; 39(5):650-8. PubMed ID: 1674585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal inhibition of adenylate cyclase. A crucial role for Mg2+.
    Bockaert J; Cantau B; Sebben-Perez M
    Mol Pharmacol; 1984 Sep; 26(2):180-6. PubMed ID: 6541292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and biochemical characterization of the D-1 dopamine receptor mediating acetylcholine release in rabbit retina.
    Hensler JG; Cotterell DJ; Dubocovich ML
    J Pharmacol Exp Ther; 1987 Dec; 243(3):857-67. PubMed ID: 2961878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
    Lau YS; Runice C; Dowd F
    J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
    Lévesque D; Di Paolo T
    Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mu- and delta-opioid receptors inhibitorily linked to dopamine-sensitive adenylate cyclase in rat striatum display a selectivity profile toward endogenous opioid peptides different from that of presynaptic mu, delta and kappa receptors.
    Schoffelmeer AN; De Vries TJ; Hogenboom F; Mulder AH
    J Pharmacol Exp Ther; 1993 Oct; 267(1):205-10. PubMed ID: 8229747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of dopamine D2 receptors in a novel cell line (SUP1).
    Ivins KJ; Luedtke RR; Artymyshyn RP; Molinoff PB
    Mol Pharmacol; 1991 Apr; 39(4):531-9. PubMed ID: 1708089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]spiroperidol identifies a D-2 dopamine receptor inhibiting adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.
    Frey EA; Cote TE; Grewe CW; Kebabian JW
    Endocrinology; 1982 Jun; 110(6):1897-904. PubMed ID: 7075543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
    Creese I; Sibley DR; Leff SE
    Fed Proc; 1984 Oct; 43(13):2779-84. PubMed ID: 6383871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration blocks chronic sulpiride-induced desensitization of striatal D1 receptor-stimulated adenylate cyclase activity in male rats.
    Ryan-Jastrow T; Gnegy ME
    J Pharmacol Exp Ther; 1989 Feb; 248(2):626-31. PubMed ID: 2521900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.